ArticleScientific reports2026
Limited predictive value of Padua and Caprini scores for venous thromboembolism in AECOPD patients with atrial fibrillation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Venous thromboembolism (VTE) risk is elevated in acute exacerbations of COPD (AECOPD), especially with coexisting atrial fibrillation (AF). However, the Caprini and Padua scores, validated in surgical or general medical populations, may not capture thrombotic risk in AECOPD-AF patients, and their predictive performance in this subgroup remains unclear. In this multicenter prospective cohort study, we analyzed 13,108 AECOPD patients (including 755 with AF and 12,353 without AF) from ten tertiary hospitals in China. Propensity score matching (1:4 ratio) was performed based on age, gender, smoking status, hypertension, stroke, and chronic renal insufficiency. Multivariable logistic regression was used to assess VTE risk factors, and the discriminatory performance of the Caprini and Padua scores was evaluated through receiver operating characteristic analysis. AF independently increased VTE risk (adjusted OR 1.55, 95% CI 1.03-2.33). Both scores showed suboptimal discrimination (Caprini AUC 0.616; Padua AUC 0.593), with no significant difference (DeLong's P = 0.349). AECOPD-AF patients exhibited higher VTE events (72/755, 9.5% vs. 150/3020, 5.0%, P < 0.001). AF constitutes an independent risk factor for VTE in the AECOPD-AF population. However, the Caprini and Padua scores show limited predictive value in this subgroup, underscoring the need for a tailored risk assessment tool specifically designed for AECOPD-AF patients.Trial registration: Chinese clinical trial registry, ChiCTR2100044625.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.